Title:
ANTICANCER AGENT
Document Type and Number:
WIPO Patent Application WO/2016/204193
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a cancer treatment drug having excellent therapeutic effect. The present invention combines a CBP/catenin inhibitor and an immune checkpoint inhibitor for treating cancer, and, as a result, not only the therapeutic effect against cancer is increased but treatment can be also effectively performed on patients with cancer less susceptible to the immune checkpoint inhibitor alone.
Inventors:
ODAGAMI TAKENAO (JP)
KOUJI HIROYUKI (JP)
OZAWA YOICHI (JP)
HORI YUSAKU (JP)
KOUJI HIROYUKI (JP)
OZAWA YOICHI (JP)
HORI YUSAKU (JP)
Application Number:
PCT/JP2016/067843
Publication Date:
December 22, 2016
Filing Date:
June 15, 2016
Export Citation:
Assignee:
PRISM PHARMA CO LTD (JP)
EISAI R&D MAN CO LTD (JP)
EISAI R&D MAN CO LTD (JP)
International Classes:
A61K45/06; A61K31/519; A61K31/53; A61K39/395; A61P35/00; A61P43/00
Domestic Patent References:
| WO2014061826A1 | 2014-04-24 | |||
| WO2015098853A1 | 2015-07-02 |
Foreign References:
| JP2014509298A | 2014-04-17 | |||
| JP2011522037A | 2011-07-28 |
Other References:
LENZ, H.J. ET AL.: "Safely targeting cancer stem cells via selective catenin coactivator antagonism", CANCER SCI., vol. 105, no. 9, September 2014 (2014-09-01), pages 1087 - 1092, XP055338772, ISSN: 1349-7066
EMAMI, K.H. ET AL.: "A small molecule inhibitor of beta-cate nin/CREB-binding protein transcription", PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 24 August 2004 (2004-08-24), pages 12682 - 12687, XP002699746, ISSN: 1091-6490
MIYUKI AZUMA: "Cancer immunotherapy by blockade of PD-1 immune checkpoint", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 244, no. 9, 2 March 2013 (2013-03-02), pages 809 - 815, XP008184468, ISSN: 0039-2359
MAHONEY, K.M. ET AL.: "The Next Immune-Checkpoint inhibitors: PD-1/PD-L1 Blockade in Melanoma", CLIN. THER., vol. 37, no. 4, April 2015 (2015-04-01), pages 764 - 782, XP055285031, ISSN: 0149-2918
KIM, T. ET AL.: "Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma", CANCER BIOL. MED., vol. 11, no. 4, December 2014 (2014-12-01), pages 237 - 246, XP002759549, ISSN: 2095-3941
See also references of EP 3311841A4
EMAMI, K.H. ET AL.: "A small molecule inhibitor of beta-cate nin/CREB-binding protein transcription", PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 24 August 2004 (2004-08-24), pages 12682 - 12687, XP002699746, ISSN: 1091-6490
MIYUKI AZUMA: "Cancer immunotherapy by blockade of PD-1 immune checkpoint", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 244, no. 9, 2 March 2013 (2013-03-02), pages 809 - 815, XP008184468, ISSN: 0039-2359
MAHONEY, K.M. ET AL.: "The Next Immune-Checkpoint inhibitors: PD-1/PD-L1 Blockade in Melanoma", CLIN. THER., vol. 37, no. 4, April 2015 (2015-04-01), pages 764 - 782, XP055285031, ISSN: 0149-2918
KIM, T. ET AL.: "Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma", CANCER BIOL. MED., vol. 11, no. 4, December 2014 (2014-12-01), pages 237 - 246, XP002759549, ISSN: 2095-3941
See also references of EP 3311841A4
Attorney, Agent or Firm:
TAKASHIMA, HAJIME (JP)
Takashima 1 (JP)
Takashima 1 (JP)
Download PDF:
Previous Patent: CRYSTALLINE SILICON SOLAR CELL MODULE AND MANUFACTURING METHOD FOR SAME
Next Patent: AIR CONDITIONER
Next Patent: AIR CONDITIONER